A little hope for women with breast cancer. And for good reason, patients suffering from an aggressive form of the disease will have access to an innovative treatment that can extend their lifespan by several months. Something to continue to hope for, the time to find other therapies.
If breast cancer is treated better and better in France, this is not the case with what doctors call the "triple negative" and which affects 15% of patients, that is to say 9,000 new cases. every year. This form of pathology has no marker on the surface of cancer cells and can only respond to targeted and heavy therapy. The five-year survival rate is 11.3% and has not changed over the past twenty years. Of the patients with “triple negative”, 40% are under 40 years old.
This new therapy, manufactured by the American laboratory Gilead, consists of an antibody treatment combined with chemotherapy and is intended for women said to be "in treatment failure" after having already received two other treatments.
closevolume_off
ACCESS IN FRANCE FROM NOVEMBER 1
The first results are rather encouraging with a median progression-free survival of these tumors of four months. The median overall survival is also doubled (12.1 months, compared to 6.7 months with chemotherapy).
Asked by AFP, the oncologist at the Institut Curie Delphine Loirat - who evaluated this therapy -, is optimistic: "It's real progress, we had never had such good results in this situation for metastatic triple negative breast cancer ”.
Regarding the availability of this treatment in France, the Minister of Health Olivier Véran recently announced to the National Assembly that Trodelvy - the drug in question - will be available in France with early access from November 1.
No comments:
Post a Comment